Mesenteric fibrosis in patients with small intestinal neuroendocrine tumors is associated with enrichment of alpha‐smooth muscle actin‐positive fibrosis and COMP‐expressing stromal cells
Open Access
- 21 January 2024
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 36 (2) , e13364
Abstract
Neuroendocrine tumors of the small intestine (SI‐NETs) often develop lymph node metastasis (LNM)‐induced mesenteric fibrosis (MF). MF can cause intestinal obstruction as well as ischemia and render surgical resection technically challenging. The underlying pathomechanisms of MF are still not well understood. We examined mesenteric LNM and the surrounding stroma compartment from 24 SI‐NET patients, including 11 with in situ presentation of strong MF (MF+) and 13 without MF (MF−). Differential gene expression was assessed with the HTG EdgeSeq Oncology Biomarker Panel comparing MF+ with MF− within LNM and paired stromal samples, respectively. Most interesting differentially expressed genes were validated by reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR) in combination with validation of associated protein levels utilizing immunohistochemistry (IHC) staining of MF+ and MF– formalin‐fixed, paraffin‐embedded (FFPE) patient samples. Overall, 14 genes measured with a 2549‐gene expression panel were differentially expressed in MF+ patients compared to MF−. Of those, nine were differentially expressed genes in LNM and five genes in the stromal tissue (>2‐fold change, p < .05). The top hits included increased COMP and COL11A1 expression in the stroma of MF+ patients compared to MF−, as well as decreased HMGA2, COL6A6, and SLC22A3 expression in LNM of MF+ patients compared to LNM of MF− patients. RT‐qPCR confirmed high levels of COMP and COL11A1 in stroma samples of MF+ compared to MF− patients. IHC staining confirmed the enrichment of α‐smooth muscle actin‐positive fibrosis in MF+ compared to MF− patients with corresponding increase of COMP‐expressing stromal cells in MF+. Since COMP is associated with the known driver for fibrosis development transforming growth factor beta and with a cancer‐associated fibroblasts enriched environment, it seems to be a promising new target for MF research.Keywords
This publication has 31 references indexed in Scilit:
- Molecular mechanisms of epithelial–mesenchymal transitionNature Reviews Molecular Cell Biology, 2014
- Cartilage Oligomeric Matrix Protein in Idiopathic Pulmonary FibrosisPLOS ONE, 2013
- Epithelial-Mesenchymal Transition Is a Critical Step in Tumorgenesis of Pancreatic Neuroendocrine TumorsCancers, 2012
- TGF-β signaling in fibrosisGrowth Factors, 2011
- Identification of Prognostic Molecular Features in the Reactive Stroma of Human Breast and Prostate CancerPLOS ONE, 2011
- Neuroendocrine tumors of the small bowels are on the rise: Early aspects and managementWorld Journal of Gastrointestinal Endoscopy, 2010
- Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor βAnnals of the Rheumatic Diseases, 2009
- Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome)Best Practice & Research Clinical Gastroenterology, 2005
- Characterization of Human and Mouse Cartilage Oligomeric Matrix ProteinGenomics, 1994
- Surgical treatment of mid‐gut carcinoid tumorsWorld Journal of Surgery, 1990